GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Debt-to-EBITDA

Oxurion NV (XBRU:OXUR) Debt-to-EBITDA : -0.53 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxurion NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €12.22 Mil. Oxurion NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.12 Mil. Oxurion NV's annualized EBITDA for the quarter that ended in Dec. 2023 was €-23.45 Mil. Oxurion NV's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Oxurion NV's Debt-to-EBITDA or its related term are showing as below:

XBRU:OXUR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67   Med: -0.26   Max: -0.04
Current: -0.67

During the past 13 years, the highest Debt-to-EBITDA Ratio of Oxurion NV was -0.04. The lowest was -0.67. And the median was -0.26.

XBRU:OXUR's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs XBRU:OXUR: -0.67

Oxurion NV Debt-to-EBITDA Historical Data

The historical data trend for Oxurion NV's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Debt-to-EBITDA Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.04 -0.44 -0.26 -0.67

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -0.33 -0.22 -0.80 -0.53

Competitive Comparison of Oxurion NV's Debt-to-EBITDA

For the Biotechnology subindustry, Oxurion NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Debt-to-EBITDA falls into.



Oxurion NV Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxurion NV's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.217 + 0.117) / -18.552
=-0.66

Oxurion NV's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.217 + 0.117) / -23.454
=-0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Oxurion NV  (XBRU:OXUR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Oxurion NV Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxurion NV (XBRU:OXUR) Business Description

Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines